ストックスクリーナーアプリを入手
30.98
1.15%
-0.33
前日終値:
$31.31
開ける：
$30.97
24時間の取引高:
276.00K
Relative Volume:
0.38
時価総額：
$1.39B
収益：
-
当期純損益:
$-47.20M
株価収益率:
-19.79
EPS:
-1.5653
ネットキャッシュフロー:
$-43.65M
1週間 パフォーマンス:
-11.67%
1か月 パフォーマンス:
-14.15%
6か月 パフォーマンス:
+167.97%
1年 パフォーマンス:
+175.11%
1日の値動き範囲:
$30.01
$31.86
1週間の範囲:
$30.01
$34.26
52週間の値動き範囲:
$4.8069
$44.89
Mbx Biosciences Inc Stock (MBX) Company Profile
Compare MBX vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MBX
Mbx Biosciences Inc
|
30.86 | 1.41B | 0 | -47.20M | -43.65M | -1.5653 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.69 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
765.88 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
726.14 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
323.44 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
290.22 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Mbx Biosciences Inc Stock (MBX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-28 | 開始されました | Barclays | Overweight |
| 2025-12-04 | 開始されました | Goldman | Sell |
| 2025-11-04 | 開始されました | TD Cowen | Buy |
| 2025-10-15 | 開始されました | Truist | Buy |
| 2025-08-15 | 再開されました | Jefferies | Buy |
| 2025-08-05 | 開始されました | Mizuho | Outperform |
| 2025-07-16 | 開始されました | Oppenheimer | Outperform |
| 2025-04-10 | 開始されました | Citizens JMP | Mkt Outperform |
| 2024-10-08 | 開始されました | Guggenheim | Buy |
| 2024-10-08 | 開始されました | JP Morgan | Overweight |
| 2024-10-08 | 開始されました | Jefferies | Buy |
| 2024-10-08 | 開始されました | Stifel | Buy |
すべてを表示
Mbx Biosciences Inc (MBX) 最新ニュース
TD Asset Management Inc Lowers Position in MBX Biosciences, Inc. $MBX - MarketBeat
Loss Report: Is MBX Biosciences Inc benefiting from interest rate changesTrend Reversal & Technical Buy Zone Confirmations - baoquankhu1.vn
MBX Biosciences annonce une offre d'actions après un doublement de l'action - TradingView
MBX SEC FilingsMBX Biosciences Inc 10-K, 10-Q, 8-K Forms - Stock Titan
MBX: Phase III and obesity data milestones, robust pipeline, and strong cash position drive outlook - TradingView
MBX: Clinically validated platform and robust pipeline drive multiple catalysts and strong financial outlook - TradingView
Tech Rally: Is MBX Biosciences Inc benefiting from interest rate changesQuarterly Portfolio Report & High Conviction Buy Zone Alerts - baoquankhu1.vn
MBX Biosciences, Inc. (NASDAQ:MBX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
MBX Biosciences Calls 2026 “Pivotal” With Phase 3 Plans, Obesity Program, and $460M Cash Runway - Yahoo Finance
MBX Biosciences, Inc. (MBX) Stock Report: Analyzing a 74% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
MBX Biosciences (MBX) CEO exercises stock options into 28,768 shares - Stock Titan
MBX Biosciences Says CFO to Step Down; Names Interim Finance Chief - marketscreener.com
MBX Biosciences Announces CFO Transition and Interim Appointment - TipRanks
MBX Biosciences announces CFO transition and new lease for Massachusetts facility - Investing.com
MBX appoints John Smither as Interim CFO as Richard Bartram to resign - TradingView
MBX Biosciences (Nasdaq: MBX) adds Burlington lab, names interim CFO - Stock Titan
MBX: Major clinical milestones and strong financials position for leadership in endocrine and obesity therapies - TradingView
UBS Maintains Buy on MBX Biosciences, Inc. Common Stock (MBX) Feb 2026 - Meyka
UBS reiterates Buy on MBX Biosciences stock, keeps $60 target - Investing.com Australia
UBS reiterates Buy on MBX Biosciences stock, keeps $60 target By Investing.com - Investing.com South Africa
Breakouts Watch: Is MBX Biosciences Inc stock influenced by commodity prices2025 Price Targets & Free Community Supported Trade Ideas - baoquankhu1.vn
Aug Fed Impact: Whats the profit margin of SCCRBond Market & Breakout Confirmation Alerts - baoquankhu1.vn
MBX Biosciences to Participate in Upcoming March Investor Conferences - Bitget
How resilient is MBX Biosciences Inc. stock in market downturns2025 Market Outlook & Real-Time Volume Trigger Notifications - mfd.ru
MBX Biosciences, Inc. (MBX) Stock Analysis: Exploring a 63.98% Potential Upside in Biotech Innovation - DirectorsTalk Interviews
MBX Biosciences (NASDAQ:MBX) Stock Price Down 6.5%What's Next? - MarketBeat
Readystate Asset Management LP Acquires New Shares in MBX Biosciences, Inc. $MBX - MarketBeat
Can MBX Biosciences Inc. stock attract ESG capital inflowsInflation Watch & Weekly Watchlist for Hot Stocks - mfd.ru
Big Money Moves: Is MBX Biosciences Inc. stock influenced by commodity pricesQuarterly Portfolio Summary & Growth Focused Entry Point Reports - mfd.ru
How MBX Biosciences Inc. stock benefits from tech adoptionQuarterly Portfolio Summary & Safe Capital Growth Trade Ideas - mfd.ru
Growth Recap: Is Magna International Inc a turnaround storyQuarterly Investment Review & AI Driven Stock Reports - baoquankhu1.vn
Fed Watch: Is MBX Biosciences Inc being accumulated by smart moneyQuarterly Trade Report & Consistent Profit Focused Trading Strategies - baoquankhu1.vn
Assessing MBX Biosciences (MBX) Valuation After Positive Analyst Sentiment And Pipeline Progress - Sahm
MBX Biosciences, Inc. (MBX) Stock Analysis: A Biotech With A 60.79% Potential Upside - DirectorsTalk Interviews
MBX Biosciences (NASDAQ:MBX) Shares Up 8.5%Still a Buy? - MarketBeat
How Much Upside is Left in MBX Biosciences, Inc. (MBX)? Wall Street Analysts Think 80.6% - MSN
Is MBX Biosciences Inc. stock influenced by commodity prices - mfd.ru
MBX Biosciences execs join Feb–Mar health investor events - Stock Titan
MBX Biosciences to Participate in Upcoming Investor Conferences - The Manila Times
Wellington discloses 7.46% MBX Biosciences (MBX) holding for clients - Stock Titan
Profit Recap: Is MBX Biosciences Inc being accumulated by smart moneyWeekly Market Report & Community Driven Trade Alerts - baoquankhu1.vn
MBX Biosciences, Inc. (MBX) Stock Analysis: Biotech Innovator with 69.49% Potential Upside - DirectorsTalk Interviews
MBX Biosciences raises $87.1 million through at-the-market stock offering - Investing.com UK
MBX Biosciences raises $87.1 million through at-the-market stock offering By Investing.com - Investing.com South Africa
MBX Biosciences Raises $87 Million in ATM Offering - TipRanks
MBX Biosciences, Inc. (NASDAQ:MBX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
MBX Biosciences (NASDAQ:MBX) Sees Strong Trading VolumeHere's What Happened - MarketBeat
Universal Beteiligungs und Servicegesellschaft mbH Takes Position in MBX Biosciences, Inc. $MBX - MarketBeat
A Look At MBX Biosciences (MBX) Valuation After New Barclays Overweight Coverage - Sahm
How Investors Are Reacting To MBX Biosciences (MBX) Adding Veteran CFO Laurie Stelzer To Its Board - Sahm
MBX Biosciences, Inc. (MBX) Stock Analysis: A Biotech Bet With 65.85% Upside Potential - DirectorsTalk Interviews
Mbx Biosciences Inc (MBX) 財務データ
収益
当期純利益
現金流量
EPS
3.97%
大文字化:
|
ボリューム (24 時間):